Fred Aslan, Artiva CEO
November 2, 2022 10:46 AM EDT
Financing
Startups
Cell/Gene Tx

An NK cell ther­a­py biotech pulls IPO am­bi­tions weeks af­ter sec­ond tri­al clear­ance

Kyle LaHucik

Senior Reporter

Arti­va Bio­ther­a­peu­tics has elect­ed not to move for­ward with an IPO. The San Diego cell ther­a­py de­vel­op­er qui­et­ly dis­closed its plans not to wade in­to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times